MedTrace Logo

TB Host Directed Therapy

NCT02968927 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-01-10

No results posted yet for this study

Summary

To examine the safety and preliminary efficacy of multiple adjunctive host directed TB therapies (TB HDT), to assess their potential to shorten TB treatment and/or prevent permanent lung damage.

Conditions

Interventions

DRUG

Everolimus 0.5 MG

DRUG

Auranofin 6 MG

DRUG

Vitamin D3

DRUG

CC-11050

DRUG

2HRbZE/4HRb

Sponsors & Collaborators

  • The Aurum Institute NPC

    lead OTHER

Principal Investigators

  • Robert S Wallis, MD,FIDSA · The Aurum Institute NPC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-09-30
Completion
2020-12-31

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02968927 on ClinicalTrials.gov